BR9813542A - Combinações de estatina-éter carboxialquìlico - Google Patents

Combinações de estatina-éter carboxialquìlico

Info

Publication number
BR9813542A
BR9813542A BR9813542-2A BR9813542A BR9813542A BR 9813542 A BR9813542 A BR 9813542A BR 9813542 A BR9813542 A BR 9813542A BR 9813542 A BR9813542 A BR 9813542A
Authority
BR
Brazil
Prior art keywords
statin
combinations
ether
carboxyalkyl ether
carboxyalkyl
Prior art date
Application number
BR9813542-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9813542A publication Critical patent/BR9813542A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9813542-2A 1997-12-12 1998-11-20 Combinações de estatina-éter carboxialquìlico BR9813542A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6937597P 1997-12-12 1997-12-12
PCT/US1998/024679 WO1999030704A1 (en) 1997-12-12 1998-11-20 Statin-carboxyalkylether combinations

Publications (1)

Publication Number Publication Date
BR9813542A true BR9813542A (pt) 2000-10-10

Family

ID=22088573

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813542-2A BR9813542A (pt) 1997-12-12 1998-11-20 Combinações de estatina-éter carboxialquìlico

Country Status (30)

Country Link
EP (1) EP1045691B1 (enExample)
JP (1) JP2002508320A (enExample)
KR (1) KR20010033003A (enExample)
AR (1) AR017851A1 (enExample)
AT (1) ATE285762T1 (enExample)
AU (1) AU754089B2 (enExample)
BR (1) BR9813542A (enExample)
CA (1) CA2304612A1 (enExample)
CO (1) CO4970816A1 (enExample)
CR (1) CR5926A (enExample)
CU (1) CU20000140A7 (enExample)
DE (1) DE69828442T2 (enExample)
DK (1) DK1045691T3 (enExample)
ES (1) ES2230733T3 (enExample)
GT (1) GT199800196A (enExample)
HN (1) HN1998000185A (enExample)
HU (1) HUP0004547A3 (enExample)
IL (1) IL135349A0 (enExample)
IS (1) IS2150B (enExample)
MY (1) MY118381A (enExample)
NO (1) NO20002966D0 (enExample)
NZ (1) NZ503982A (enExample)
PA (1) PA8464601A1 (enExample)
PE (1) PE20000017A1 (enExample)
PL (1) PL341066A1 (enExample)
PT (1) PT1045691E (enExample)
SV (1) SV1998000146A (enExample)
UY (1) UY25299A1 (enExample)
WO (1) WO1999030704A1 (enExample)
ZA (1) ZA9811348B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US20030105154A1 (en) 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
PL343851A1 (en) * 1997-12-12 2001-09-10 Warner Lambert Co Antihyperlipidemic statin-lp(a) inhibitor combinations
CZ20011035A3 (cs) * 1998-09-30 2001-10-17 Warner-Lambert Company Léčivo pro prevenci nebo oddálení revaskularizace pomocí katetru u pacientů postiľených chorobou koronární artérie
US6562864B1 (en) * 1999-09-02 2003-05-13 Drake Larson Catechin multimers as therapeutic drug delivery agents
IN191580B (enExample) * 1999-12-17 2003-12-06 Ranbaxy Lab Ltd
SK10622002A3 (sk) 2000-01-25 2003-07-01 Warner-Lambert Company Étery dikarboxylátu vápenatého, metódy ich výroby a ich využitie na liečbu vaskulárnych chorôb a diabetu
WO2001078747A1 (de) * 2000-04-18 2001-10-25 Bayer Aktiengesellschaft Verwendung von cse-hemmern zur behandlung von herzinsuffizienz
MXPA02009662A (es) * 2000-04-26 2003-03-10 Warner Lambert Co Agentes antihipertensivos y su uso.
US6689807B1 (en) 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
NZ529913A (en) * 2001-08-16 2005-03-24 Teva Pharma Processes for preparing calcium salt forms of statins
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
MX367352B (es) * 2012-01-06 2019-08-16 Gemphire Therapeutics Inc Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.
EP3370703A4 (en) 2015-11-06 2019-06-19 Gemphire Therapeutics Inc. GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases

Also Published As

Publication number Publication date
DE69828442D1 (de) 2005-02-03
GT199800196A (es) 2000-06-03
HN1998000185A (es) 1999-06-02
EP1045691A1 (en) 2000-10-25
DK1045691T3 (da) 2005-03-14
PA8464601A1 (es) 2001-12-14
IS2150B (is) 2006-10-13
KR20010033003A (ko) 2001-04-25
CA2304612A1 (en) 1999-06-24
ES2230733T3 (es) 2005-05-01
HUP0004547A2 (hu) 2001-05-28
NO20002966L (no) 2000-06-09
PL341066A1 (en) 2001-03-26
PT1045691E (pt) 2005-03-31
NZ503982A (en) 2002-03-28
CR5926A (es) 2000-03-06
AU754089B2 (en) 2002-11-07
DE69828442T2 (de) 2005-06-02
ZA9811348B (en) 1999-06-14
AU1591599A (en) 1999-07-05
CO4970816A1 (es) 2000-11-07
SV1998000146A (es) 1999-09-30
PE20000017A1 (es) 2000-01-20
IL135349A0 (en) 2001-05-20
EP1045691B1 (en) 2004-12-29
NO20002966D0 (no) 2000-06-09
IS5445A (is) 2000-04-14
MY118381A (en) 2004-10-30
JP2002508320A (ja) 2002-03-19
AR017851A1 (es) 2001-10-24
WO1999030704A1 (en) 1999-06-24
HUP0004547A3 (en) 2001-12-28
ATE285762T1 (de) 2005-01-15
CU20000140A7 (es) 2005-10-19
UY25299A1 (es) 2001-08-27

Similar Documents

Publication Publication Date Title
BR9813542A (pt) Combinações de estatina-éter carboxialquìlico
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
MX2009003920A (es) Estatina y acidos grasos omega 3 para reducir los niveles de apo b.
EP1604664A4 (en) MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
BG105559A (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
BG104075A (en) Combined treatment including atorvastatin and an antihypertonic form
HUP0203556A2 (hu) Oxkarbazepint tartalmazó gyógyszerkészítmények és alkalmazásuk
BR9915267A (pt) Métodos de tratamento, prevenção ou redução derisco de doença de alzheimer
BRPI0308663B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
AU2003278816A1 (en) ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
ES2161548T3 (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa.
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
AU7031500A (en) Therapeutic quinazoline compounds
EE04356B1 (et) aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis
PE20001325A1 (es) Combinacion de cerivastatina y fibratos
MXPA05012755A (es) Nitrooxiderivados de fluvastatina, pravastatina, cerivastatina, atorvastatina y rosuvastatina como agentes reductores del colesterol con mejor actividad anti-inflamatoria, anti-trombotica y anti-plaquetaria.
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
BR0213181A (pt) Combinações de inibidor de cox-2
BR0008382A (pt) Formulação de liberação controlada para tratamento de copd
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
NO996206D0 (no) Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
NO990450L (no) Behandling av sinnslidelser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1771 DE 20041214 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL:A61K 31/19, A61K 31/49, A61K 31/44, A61K 31/47, A61K 31/365, A61K 31/35 , A61K 31/505, A61P 3/06, A61P 07/04, A61P 9/10

Ipc: A61K 31/19 (2008.04), A61K 31/40 (2008.04), A61K 3

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.